1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Artelo Biosciences, Inc.

Artelo Biosciences, Inc.

ARTLW
Artelo Biosciences, Inc.US flagNASDAQ Capital Market
0.01
USD
- -
- -
13,069.00Market Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
-2
-2
-5
-7
-10
-9
-10
-13
-13
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
1
- -
3
2
10
17
10
1
-3
5
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
1
- -
5
4
12
19
12
3
-1
7
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
2
1
10
Cash, Cash Equivalents & STI
2
1
10
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
4
6
Payables & Accruals
4
3
5
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-852.6%
2.45%
-144.52%
Free Cash Flow
199.83%
15.59%
2.04%
Net Income, GAAP
191.49%
24.86%
31.07%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Gregory D. Gorgas
Full Time Employees
5
Sector
Healthcare
Industry
Biotechnology
Address
505 Lomas Santa Fe Solana Beach NV United States of America 92075
IPO Date
Jun 21, 2019
CIK
0001621221
Website
artelobio.com
Similar Companies
Santhera Pharmaceuticals Holding AG (SPHDF)
Botanix Pharmaceuticals Limited (BXPHF)
Senti Biosciences, Inc. (SNTI)
Bone Therapeutics S.A. (BOTHE.BR)
C4 Therapeutics, Inc. (CCCC)
Kiromic BioPharma, Inc. (KRBP)
Business
Artelo Biosciences, Inc. (Nasdaq: ARTLW) is a clinical-stage biopharmaceutical company that develops and commercializes proprietary therapeutics modulating lipid-signaling pathways, including the endocannabinoid system, to address unmet needs in cancer, pain, anxiety, dermatologic conditions, inflammation, and anorexia; its lead product candidates include ART27.13, a peripherally restricted synthetic dual CB1/CB2 receptor agonist in Phase 2 for cancer-related anorexia and weight loss with interim data showing +6.4% weight gain, ART26.12, a selective FABP5 inhibitor that completed Phase 1 single ascending dose trials and advances toward multiple ascending dose studies for chemotherapy-induced peripheral neuropathy with preclinical efficacy in psoriasis, osteoarthritis, and cancers, and ART12.11, a patented cannabidiol-tetramethylpyrazine cocrystal enhancing CBD bioavailability for anxiety, depression, and pain; the company additionally maintains a proprietary library of FABP inhibitors targeting FABP3, FABP5, and FABP7 for neuropathic pain, cancer, and metabolic disorders. Founded in 2017 through a reverse merger and headquartered at 505 Lomas Santa Fe Drive, Suite 160, Solana Beach, California, USA, with a UK subsidiary in Alderley Edge, Cheshire, Artelo operates primarily in the United States and pursues global intellectual property with issued US patents and pending international applications. Recent developments encompass a $9.475 million at-the-market private placement in August 2025 to initiate a Solana cryptocurrency treasury strategy as the first publicly traded pharma adopter of SOL reserves, a $3.0 million confidentially marketed public offering and $0.4 million ATM proceeds in Q3 2025, publication of peer-reviewed preclinical data in December 2025 demonstrating a FABP5 inhibitor's efficacy in reducing stress-induced anxiety and depression, expanded partnering interest for ART27.13 and ART26.12 from pharmaceutical companies, and presentations at ICRS 2025 highlighting ART12.11's alleviation of stress-induced depressive symptoms.